Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$1.4M
Filings
77
Firms Hired
2
Active Period
2011–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Patients Deserve Price Tags Act
2026 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags
Client expense: — · Firm income: $40,000
Matched citations: S 2355
Role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags; Medicare payment for Software as a Medical Service (SaMS)
Client expense: $160,000 · Firm income: —
Matched citations: S 2355
Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;
Client expense: — · Firm income: —
Matched citations: S 2355
Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;
Client expense: — · Firm income: —
Matched citations: S 2355
Role of molecular profiling in cancer care; access to molecular profiling technologies in Medicare; prior authorization reform in Medicare; Date of Service Rule Reform for lab services; Medicare payment for Software as a Medical Service (SaMS); appropriate reimbursement for cutting edge cancer diagnostic testing, including PAMA reporting; role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags;
Client expense: — · Firm income: —
Matched citations: S 2355
Patients Deserve Price Tags Act
2026 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
Role of Artificial Intelligence and technology in cancer diagnostics and treatment; Value of precision medicine and blood-based diagnostic tools; S 2355, Patients Deserve Price Tags
Client expense: — · Firm income: $40,000
Matched citations: S 2355
Role of molecular profiling in cancer care; access to molecular profiling technologies and multi-cancer testing in Medicare; prior authorization reform in Medicare and appropriate reimbursement for cutting edge cancer diagnostic testing; HR 5269 RESULTS Act; HR 7148 the Consolidated Appropriations Act of 2026; updated timing of reporting under PAMA
Client expense: — · Firm income: $40,000
Matched citations: HR 5269
Consolidated Appropriations Act, 2026
2026 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
Role of molecular profiling in cancer care; access to molecular profiling technologies and multi-cancer testing in Medicare; prior authorization reform in Medicare and appropriate reimbursement for cutting edge cancer diagnostic testing; HR 5269 RESULTS Act; HR 7148 the Consolidated Appropriations Act of 2026; updated timing of reporting under PAMA
Client expense: — · Firm income: $40,000
Matched citations: HR 7148
Telehealth Modernization Act
2025 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
Role of molecular profiling in cancer care; access to molecular profiling technologies and multi-cancer testing in Medicare; HR 5081, Telehealth Modernization Act, prior authorization reform in Medicare and appropriate reimbursement for cutting edge cancer diagnostic testing; HR 5269 RESULTS Act
Client expense: — · Firm income: $40,000
Matched citations: HR 5081
Role of molecular profiling in cancer care; access to molecular profiling technologies and multi-cancer testing in Medicare; HR 5081, Telehealth Modernization Act, prior authorization reform in Medicare and appropriate reimbursement for cutting edge cancer diagnostic testing; HR 5269 RESULTS Act
Client expense: — · Firm income: $40,000
Matched citations: HR 5269
Telehealth Modernization Act
2025 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Role of molecular profiling in cancer care; access to molecular profiling technologies and multi-cancer testing in Medicare; HR 5081, Telehealth Modernization Act, prior authorization reform in Medicare and appropriate reimbursement for cutting edge cancer diagnostic testing
Client expense: — · Firm income: $40,000
Matched citations: HR 5081
American Relief Act, 2025
2024 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests; HR 10545 American Relief Act of 2025
Client expense: — · Firm income: $40,000
Matched citations: HR 10545
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
Appropriate regulation of Artificial Intelligence used in cancer diagnostic testing; HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act
Client expense: — · Firm income: $40,000
Matched citations: HR 1691
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests; HR 10545 American Relief Act of 2025
Client expense: — · Firm income: $40,000
Matched citations: HR 2407
Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests; HR 10545 American Relief Act of 2025
Client expense: — · Firm income: $40,000
Matched citations: S 2085
Ensuring Patient Access to Critical Breakthrough Products Act of 2024
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Appropriate regulation of Artificial Intelligence used in cancer diagnostic testing; HR 8816 American Medical Innovation and Investment Act; HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act
Client expense: — · Firm income: $40,000
Matched citations: HR 1691
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Client expense: — · Firm income: $40,000
Matched citations: HR 2407
American Medical Innovation and Investment Act of 2024
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Appropriate regulation of Artificial Intelligence used in cancer diagnostic testing; HR 8816 American Medical Innovation and Investment Act; HR 1691 Ensuring Patient Access to Critical Breakthrough Products Act
Client expense: — · Firm income: $40,000
Matched citations: HR 8816
Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Client expense: — · Firm income: $40,000
Matched citations: S 2085
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Client expense: — · Firm income: $40,000
Matched citations: HR 2407
American Medical Innovation and Investment Act of 2024
2024 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
Appropriate regulation of Artificial Intelligence used in cancer diagnostic testing; HR 8816 American Medical Innovation and Investment Act
Client expense: — · Firm income: $40,000
Matched citations: HR 8816
Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · second_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Client expense: — · Firm income: $40,000
Matched citations: S 2085
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Client expense: — · Firm income: $40,000
Matched citations: HR 2407
Medicare Multi-Cancer Early Detection Screening Coverage Act
2024 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; Appropriate payment and coverage criteria for certain advanced diagnostic tests
Client expense: — · Firm income: $40,000
Matched citations: S 2085
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
2023 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 2407/S 2085 The Medicare Multi-Cancer Early Detection Screening Coverage Act; PAMA lab reporting delay included in HR 6363 Further Continuing Appropriations and other Extensions Act
Client expense: — · Firm income: $40,000
Matched citations: HR 2407
Source: Senate LDA